| HOME >> MEDICINE >> TECHNOLOGY |
AUGUSTA, Ga., June 14, 2011 /PRNewswire/ -- Cardinal Health today opened its first cyclotron facility in the state of Georgia, further expanding its nationwide capability to manufacture molecular imaging biomarkers that aid in the early diagnosis, monitoring and treatment of cancer, neurological disorders and heart disease.
Cyclotrons are critical to the manufacturing process for Positron Emission Tomography (PET) molecular imaging agents, one of the fastest-growing areas of nuclear medicine. When injected into the body, these specialized radiopharmaceuticals, called biomarkers, detect and trace abnormal cellular functions that are associated with a variety of diseases. Visible using sophisticated imaging scanners, these biomarkers make it easier for physicians to non-invasively diagnose critical, life-threatening diseases in their earliest stages. They can also improve physicians' ability to track the effectiveness of patient treatment plans.
Cardinal Health's Augusta cyclotron facility will be located nearby its existing nuclear pharmacy in Augusta, where the company will dispense PET imaging agents in patient-specific doses. Cardinal Health now operates a nationwide network of 36 cyclotrons, with its Charlotte, N.C. cyclotron being the closest to Augusta.
"The introduction of our newest cyclotron in Augusta underscores Cardinal Health's commitment to making molecular imaging more accessible to physicians and patients in Georgia and throughout the United States," said John Rademacher, president of Cardinal Health's Nuclear Pharmacy Services business. "This innovative technology is an important tool in improving the quality and cost-efficiency of health care, because it helps physicians save lives by enabling them to detect serious illnesses and determine the effectiveness of related treatment plans."
The new cyclotron will also support molecular imaging research in nearby hospitals and universities, and will be available to support c
'/>"/>
| SOURCE Cardinal Health Copyright©2010 PR Newswire. All rights reserved |